Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Ivermectin
Norbrook Laboratories (Ireland) Limited
QP54AA01
Ivermectin
0.8 milligram(s)/millilitre
Oral solution
POM: Prescription Only Medicine as defined in relevant national legislation
ivermectin
Authorised
2000-06-14
Health Products Regulatory Authority 15 January 2019 CRN008TFC Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Noromectin Drench 0.8 mg/ml Oral Solution for Sheep 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE Ivermectin 0.8 mg/ml EXCIPIENT(S) Benzyl alcohol 30 mg/ml For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Oral Solution. A pale yellow clear liquid 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Sheep 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES The medicinal product is indicated for the treatment and control of gastrointestinal nematodes, lungworms, and nasal bots of sheep. GASTRO-INTESTINAL WORMS _Haemonchus contortus _[Adult, L4 and inhibited L4]_, Ostertagia (Teladorsagia) _ _circumcincta _[Adult, L4 and inhibited L4]_, Trichostrongylus axei_ [Adult and L4], _Trichostrongylus colubriformis_ [Adult and L4], _Trichostrongylus vitrinus_ [Adult and L4], _Cooperiacurticei_ [Adult and L4], _Cooperia oncophora _[Adult and L4], _Nematodirus _ _battus _[Adult and L4], _Nematodirus filicollis_ [Adult and L4], _Nematodirusspathiger_ [Adult and L4]_, Strongyloides papillosus _[Adult and L4]_, _ _Oesophagostomumcolumbianum_ [Adult and L4], _Oesophagostomum venulosum _ [Adult and L4] and adult _Chabertia ovina._ Inhibited larval stages and benzimidazole resistant strains of _H contortus_ and _Ostertagia (Teladorsagia) circumcincta_ are also controlled. LUNGWORMS (ADULT AND IMMATURE): Health Products Regulatory Authority 15 January 2019 CRN008TFC Page 2 of 5 _Dictyocaulus filaria_ NASAL BOT (ALL LARVAL STAGES):_Oestrus ovis_ 4.3 CONTRAINDICATIONS Do not use in animals in which milk is intended for human consumption. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: - Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. - Underdosing, Read the complete document